Drug intelligence / Profile preview

NBP608

Development stage: Unknown
Lead developer: SK bioscience
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

NBP608, also known as SKYVaricella, is a live, attenuated vaccine developed by SK Chemicals Co., Ltd. and SK Bioscience Co., Ltd. It is based on the Oka/SK strain of the varicella-zoster virus and is being investigated for active immunization against both zoster (shingles) in adults aged 50 and over, and varicella (chickenpox) in healthy children.

Brand names: SKYVaricella
Other names: herpes zoster vaccine liveshingles vaccine live

Beyond the preview

Go deeper on NBP608.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBP608.

Explore the full profile